Eyeing Duchenne MD cure, The Column Group gambles $40M on CRISPR/Cas9 startup Exonics – Endpoints News
Endpoints NewsEyeing Duchenne MD cure, The Column Group gambles $40M on CRISPR/Cas9 startup ExonicsEndpoints NewsThe Column Group thinks that gene editing may provide just the right kind of technology needed to cure Duchenne muscular dystrophy. And the… Continue reading
